Radioligand Therapy Market to Grow from USD 2.98 Billion in 2025 to USD 15.85 Billion by 2035, at a CAGR of 18.2% – SNS Insider

U.S. Radioligand Therapy Market to Reach USD 10.68 Billion and Europe USD 1.79 Billion by 2035 as PSMA-Targeted Therapies, Alpha-Emitter Innovation, and Expanding Isotope Production Drive Demand.

U.S. Radioligand Therapy Market to Reach USD 10.68 Billion and Europe USD 1.79 Billion by 2035 as PSMA-Targeted Therapies, Alpha-Emitter Innovation, and Expanding Isotope Production Drive Demand.

Top AI Expert: Elon Musk Buried His Most Important Filing Under the Biggest Headline of the Year, On Purpose

A new free presentation argues Musk timed a quiet FCC filing to disappear beneath his own trillion dollar IPO news, and lays out what the AI expert believes the document was designed to keep hidden.

A new free presentation argues Musk timed a quiet FCC filing to disappear beneath his own trillion dollar IPO news, and lays out what the AI expert believes the document was designed to keep hidden.

Business Rules Management System Market to Reach $4.20 Billion by 2035 as AI-Driven Decision Automation Accelerates | Research by SNS Insider

The U.S. Business Rules Management System Market is Projected to Grow from $0.47 Billion in 2025 to $1.09 Billion by 2035, While Europe is Expected to Expand from $0.54 Billion to $1.36 Billion, Driven by Real-Time Decision-Making, Regulatory Compliance, Enterprise Automation, and Rising Adoption of AI- and Machine Learning-Enabled Business Rules Platforms

The U.S. Business Rules Management System Market is Projected to Grow from $0.47 Billion in 2025 to $1.09 Billion by 2035, While Europe is Expected to Expand from $0.54 Billion to $1.36 Billion, Driven by Real-Time Decision-Making, Regulatory Compliance, Enterprise Automation, and Rising Adoption of AI- and Machine Learning-Enabled Business Rules Platforms

Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight

Emerging therapies for ulcerative colitis treatment, such as Obefazimod (Abivax), Tulisokibart (Merck), Olamkicept (Ferring Pharmaceuticals), Afimkibart (Roche), Icotrokinra (Johnson & Johnson/Protagonist Therapeutics), Duvakitug (Teva Pharmaceuticals/Sanofi), Zotemtegrast (Eli Lilly), Zasocitinib (Takeda), XmAb942 (Xencor), and others, reflect a growing ulcerative colitis market, advancing novel mechanisms to address unmet needs in moderate-to-severe disease.

Emerging therapies for ulcerative colitis treatment, such as Obefazimod (Abivax), Tulisokibart (Merck), Olamkicept (Ferring Pharmaceuticals), Afimkibart (Roche), Icotrokinra (Johnson & Johnson/Protagonist Therapeutics), Duvakitug (Teva Pharmaceuticals/Sanofi), Zotemtegrast (Eli Lilly), Zasocitinib (Takeda), XmAb942 (Xencor), and others, reflect a growing ulcerative colitis market, advancing novel mechanisms to address unmet needs in moderate-to-severe disease.

Schouw & Co. share buy-back programme, week 36 2026

On 2 January 2026, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 59 of 18 December 2025. Under the programme, Schouw & Co. will acquire shares for up to DKK 240 million during the period 2 January to 31 December 2026. As outlined in Company Announcement no. 48 of 14 August 2026, the programme was extended with up to DKK 170 million, increasing the total amount of which Schouw & Co. will acquire shares to up to DKK 410 million.

Z Traders Introduces The New Funding Model Designed to Expand Opportunities in Trading

New York, USA, Sept. 07, 2026 (GLOBE NEWSWIRE) —

Z Traders has introduced a new trading funding model designed to give eligible participants greater flexibility in accessing trading education and digital trading credits. Since launching on August 13, the company reports that more than 1,000 users have joined the platform, with participation continuing to grow.